The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.
Department of Haematology, Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, UK.
A
A
Giannoudis
Department of Haematology, Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, UK.
A
A
Davies
Department of Haematology, Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, UK.
R J
RJ
Harris
Department of Haematology, Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, UK.
C M
CM
Lucas
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
M
M
Pirmohamed
Department of Haematology, Molecular and Clinical Cancer Medicine, Royal Liverpool University Hospital, Liverpool, UK.
R E
RE
Clark
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D016022:Case-Control Studies; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011379:Prognosis; D011743:Pyrimidines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000970:Antineoplastic Agents; D001549:Benzamides; D000068877:Imatinib Mesylate; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; C114462:multidrug resistance-associated protein 3